Abstract 120: CCR5 Polymorphism - A Possible Protective Factor for Post-Stroke PTSD Symptoms

Hen Hallevi,Oren Tene,Aviva Alpernas,Jeremy Molad,Einor Ben Assayag
DOI: https://doi.org/10.1161/str.55.suppl_1.120
IF: 10.17
2024-02-01
Stroke
Abstract:Background: Current data suggest 25-30% of stroke survivors will develop post-traumatic stress disorder (PTSD) symptomatology. This common and disabling disorder is thought to be caused by exposure to a traumatic, life-threatening event. It is unrelated to stroke severity and is one of the barriers to successful recovery from the stroke. We have recently reported on the naturally occurring loss-of-function mutation (LOFM) in the C-C Chemokine receptor 5 gene (CCR5-Δ32) as a protective factor in post-stroke recovery and depression. We sought to examine whether it also prevents the development of PTSD symptoms after stroke or transient ischemic attack (TIA). Methods: Participants were survivors of first-ever mild-moderate ischemic stroke or TIA from the TABASCO prospective cohort study, who underwent a 3T MRI, and were examined by a multi-professional team 6, 12, and 24 months after the event, using direct interviews, depression scales, neurological, neuropsychological, and functional evaluations. PTSD symptoms were assessed using the PTSD Checklist (PCL). CCR5-Δ32 status and PTSD Checklist data were available for 432 patients. Results: Forty-eight participants (11%) developed probable PTSD (PCL ≥44) during the first year after the stroke/TIA. CCR5 -Δ32 carriers presented fewer PTSD symptoms (lower PCL scores) 6, 12, and 24 months after the index event, compared with non-carriers (p=0.002, p<0.001, p=0.011, respectively). The association remained significant after adjustment for age, gender, education, depression or administration of anti-depressants during the follow-up period, ethnicity, and new infarct on MRI. Compared to baseline, CCR5 -Δ32 non-carriers tended to remain stable or develop worse PTSD symptoms over time, while CCR5 -Δ32 carriers tended to improve. Conclusions: We report that carriers of the CCR5 -Δ32 allele had a lower tendency to develop PTSD symptoms post-stroke. These findings might have clinical significance in stroke recovery. They also suggest a mechanism-based treatment target for post-stroke depression. Drugs mimicking this LOFM exist and could offer a novel treatment for this serious and underdiagnosed complication of stroke.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?